MedTrace Logo

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study

NCT03464201 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-02-22

No results posted yet for this study

Summary

The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".

Conditions

Interventions

DRUG

Enzalutamide 40 MG

Enzalutamide 160 mg p.o. every day

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Apices Soluciones S.L.

    collaborator INDUSTRY

  • Grupo Español de Tumores Huérfanos e Infrecuentes

    lead OTHER

Principal Investigators

  • Garcia-Donas, MD · CIOCC (Hospital Universitario HM Sanchinarro)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-13
Primary Completion
2020-11-11
Completion
2020-11-11

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03464201 on ClinicalTrials.gov